- $5.76bn
- $5.35bn
- $672.40m
- 99
- 24
- 97
- 86
Annual income statement for Nova, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 269 | 416 | 571 | 518 | 672 |
| Cost of Revenue | |||||
| Gross Profit | 151 | 235 | 317 | 293 | 387 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 214 | 304 | 421 | 386 | 485 |
| Operating Profit | 55.6 | 112 | 150 | 132 | 188 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 56.5 | 109 | 158 | 155 | 216 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 47.9 | 93.1 | 140 | 136 | 184 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 47.9 | 93.1 | 140 | 136 | 184 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 47.9 | 93.1 | 140 | 136 | 184 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1.67 | 3.15 | 4.43 | 4.27 | 5.74 |